Amneal to Pay $88.5M in Settlement For Majority of Opioid Claims

Amneal Pharmaceuticals determined to settle a majority of opioids-related claims for $88.5 million and agreed to provide up to $177.4 million in naxolone nasal spray to help treat opioid overdoses.

• Agreement is effective on January 29
• Settling parties can receive up to 25% of the nasal spray’s value in cash during the last four years of the 10-year payment term, increasing total value of the cash agreement to $132.9 million

To view the source of this information click here

To contact the reporter on this story:
Yash Roy in Washington at yroy@bloomberg.net

To contact the editors responsible for this story: ...